Maximilian P. Pinho-Schwermann

This study shows that ONC201 is effective against prostate cancer and small cell lung carcinoma cells, regardless of neuroendocrine differentiation markers or BRN2 overexpression.

This study shows that inhibiting ITGB6 enhances anti-tumor immune responses in mouse models of head and neck and pancreatic cancers, with potential for combination immunotherapy.

This study investigates whether neuroendocrine differentiation (NED) affects sensitivity to imipridones ONC201 and ONC206 in prostate cancer cell lines, finding differential responses based on SOX2 and BRN2 overexpression.

This study shows that combining ONC201 with enzalutamide or darolutamide synergistically reduces mCRPC cell viability and PSA levels, with in vivo anti-tumor effects.